PDF companion to How to Rebuild Your Medical Device Website From Scratch *featuring 33 screen captures*





BioLife Solutions' Old Site



We develop next generation, patented hypothermic storage and cryopreservation media products that extend shelf life and improve post preservation viability and performance of cells, tissues, and organs.

Our Products

GMP, SERUM-FREE, PROTEIN-FREE BIOPRESERVATION MEDIA PRODUCTS

HypoThermosol[®] Storage and Shipping Media Proprietary, best-in-class serum-free, protein-free, GMP-grade storage/shipping media for cells, tissues, and organs

CryoStor[®]

Freeze Media Pre-Formulated with DMSO Proprietary, serum-free, protein-free, GMP-grade freeze media for cells, tissues, and organs

DI 101 8

News

THE LATEST FROM BIOLIFE SOLUTIONS

July 25, 2011 CAREERS: TWO POSITIONS read more

July 6, 2011 RECORD QUARTERLY REVENUE BioLife successfully finishes fourth consecutive month of record revenues read more

June 21, 2011 BIOLIFE LEADER IN UMBILICAL CORD BLOOD STEM CELL MASTER FILE REQUEST FORM



ISO 13485 2003 CERTIFIED

Events

Stem Cells Europe Edinburgh, Scotland July 20-21, 2011

MSC 2011 Cleveland, OH


August 22-24, 2011

ISEH 40th Annual Scientific Meeting

Vancouver, Canada

August 25-28, 2011

Screen Shot Compilation





Welcome to Vision Sciences

Pioneering in healthcare since 1990, Vision-Sciences, Inc. is a leading medical device manufacturer specializing in efficiency and infection control solutions for flexible endoscopy.


With unique, high performance flexible endoscopes, imaging technology, and the patented, innovative EndoSheath[®] Technology, Vision-Sciences is creating new frontiers in minimally invasive endoscopic procedures.


News


19-SEP-2011

Vision-Sciences' Pioneering Technology Featured on The Doctor Oz Show

10-AUG-2011










About Animas | Press Room | Worldwide | Sitemap | Contact us | Careers | Investor Relations | Privacy Policy | Notice of Privacy Practices Legal Notice | Safe Harbor Privacy Policy | Safety Information | Educational Grant Request | California Compliance | The Joint Commission | Transparency | Transparency - HCP Payments | IIS

© Animas Corporation 2007-2010. All rights reserved. Rx only. This site is intended for visitors from the United States and is published by Animas Corporation, which is solely responsible for its contents. The third-party trademarks









000



Solutions Why Accellent? About Us Contact



Many solutions. Global reach. One Accellent.

Accellent is home to the most comprehensive supply chain solutions in the world. More than a supplier, we are a strategic partner. Accellent brings customer innovations to the market quickly and efficiently-meaning revenues and profits are realized faster. That's the Accellent Advantage.

Q

With a proven track record and industry-recognized solutions, Accellent leverages a vast infrastructure of global resources. Accellent's complete menu of outsourcing solutions let our customers focus on what they do best-developing new products and therapies. Count on Accellent for the rest.



Why Accellent?

Read more »

Partner with Accellent for innovative design, unmatched

technical expertise and unrivaled industry knowledge.

Solutions by lapab Explore our comprehensive

suite of technical skills and engineering solutions. Select Options




Solutions by Market

Choose a market to learn more about our device manufacturing. Select Options - \$ 3


Careers


Join Accellent for a career full of challenging and rewarding opportunities.

Read more »









Careers | Contact Philips | Philips | Privacy policy | Terms of use | Site Map | Mobile website ©2004-2011 Koninklijke Philips Electronics N.V. All rights reserved.

Abbott



Select a Country | Site Map | Contact Us

🚇 Printer Friendly | Text Size 🚍 🖶

Enter Search

Home About Abbott Products Global Citizenship Careers News & Media Investor Relations Global Licensing



Barron's 500

Abbott Propels to Top Ranked Health Care Company on Barron's 500. »Read more

Helping the Healing Process



sergey Knyaznenkov, nussia. Adam Namionan

News

Abbott Named Top Dealmaker for Fourth Consecutive Year by The Deal

Abbott Named Top Dealmaker for Fourth Time

- Abbott Earns 100 Percent Banned Substance Free Certification for all of its EAS® Sports Nutrition Products
- Abbott Again Recognized as One of the "Top Employers" in the Biotech and Pharmaceutical Industry by Science Magazine

View more news...

Features



Citing Abbott leadership in emerging markets, U.S. magazine The Deal has named Abbott one of its "Most Admired Corporate Dealmakers" for the fourth consecutive year.



Abbott Recognized for Responsible Citizenship for Seventh Consecutive Year

For the seventh year in a row, Abbott has been named to the Dow Jones Sustainability Index (DJSI) – on both the North America and World lists – for continued leadership in responsible economic, environmental and social performance.



Abbott Provides Aid to Famine Victims in the Horn of Africa

The Abbott Fund, Abbott's philanthropic foundation, recently donated \$100,000 to humanitarian organizations working in Somalia, Ethiopia and Kenya to assist those impacted by the devastating drought and famine in those countries, where more than 12.4 million people are urgently in need of humanitarian assistance.

View more features...

Resources for ...

 Health Care Professionals

- Investors
- Job Seekers
- News & Media
- Patients & Caregivers
- Students

Abbott Worldwide



Stock Quote

NYSE:ABT	
Price	\$ 51.21
Change	🔺 +0.46
Volume	7,027,680
Intraday High	\$ 51.67
Intraday Low	\$ 50.43

Vinimum 20 minutes delayed Refresh quote

Annual Report



2010 Annual Report

PHYSIO CONTROL Lifesaving starts here.™

HOME

SOLUTIONS

PRODUCTS & SERVICES

PHYSIO-CONTROL UNIVERS

VEB STORE

Quick Links

Register Your Defibrillator

Get Product Support

Share Your Save Story

Physio-Control Web Store

Product Notices

Technical Training and Education

Solutions Customer Log In

Distributor Web Portal Access

Supplier Web Portal Access

A Story of Survival

Whatcom County Medic One, PeaceHealth St. Joseph Medical Center and survivor Nancy Olson share their experience with mechanical chest compressions

LUCAS[®] 2 CHEST COMPRESSION SYSTEM

Featured Story

On February 22, Medtronic, Inc. announced its intention to divest the Physio-Control business. Medtronic first announced plans for divestiture in 2006 and their plans have been consistent since then. With the global economic situation beginning to stabilize, the timing is right to move forward with the divestiture.

Read the letter to Customers, Partners and Industry from Brian Webster, President of Physio-Control



As you are aware, the American Heart Association (AHA) and the European Resuscitation Council (ERC) released their 2010 Guidelines for resuscitation and CPR last fall. Like you, we at Physio-Control have been closely following the scientific literature and how changes may impact protocols and patient care.

- UPDATE: Learn how Physio-Control solutions are consistent with AHA and ERC Guidelines
- 2010 AHA Guidelines Revision: Energy dosing levels
- <u>Read a Letter to Customers from Brian Webster, President of</u>
 <u>Physio-Control</u>
- Sign-up to receive our Guidelines 2010 updates via email



United States

÷

f 🕒 🚻 👔

KEYWORD SEARCH

CONTACT US

-







Innovation

READ MORE >

Mill	ar. stems. Solutions «				Home	Contact Us Login
roducts	How to Buy	About You	Quality	About Us	Support Center	Research & Papers
Product RESEA CLINIC TELEA 	RCH					
News an	d Events	5 F m Comp	ulti-segment, pressur lete cardiac function a	Pressure-Volume e-volume catheter assessment in large anim r with same proven perfo	nal models	LEARN MORE

OUR NEXT EVENT AALAS - BOOTH #527

Pro

October 4, 2011 - October 6, 2011 San Diego, CA

AMERICAN COLLEGE OF TOXICOLOGY (ACT) - BOOTH #58

November 6, 2011 - November 9, 2011 Phoenix, AZ

TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT) - BOOTH #506 November 8, 2011 - November 10, CATH - DISPUSABLE PRESSURE CATHETER May 26, 2010

ALL EVENTS ALL NEWS

Millar Instruments develops pressure-sensing technology for catheters used in medical research and clinical diagnosis.

We became pioneers in this field in 1971, and the Association for the Advancement of Medical Instrumentation (AAMI) labeled us the "gold standard" for accurate measurement in 2001. In 2008 an independent research panel also attested to the superiority of our measurements over those of our competitors.

Because our technology leadership is dependent on the input and participation of our customers - and because it directly impacts the quality of their health care research and dinical performance - we endeavor daily to maintain and increase the

Products

How to Buy About You **Distributor Directory**

About Us

Quality

Support Center

Research & Papers

Business Partners







LATEST NEWS > more news

Sept. 27, 2011 Merck Names Cuong Viet Do as Chief Strategy Officer

Sept. 23, 2011 Study of ZOLINZA[®] (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint

Sept. 20, 2011 Merck Joins Global Fight to Help Save Women's Lives During Pregnancy and Childbirth

MERCK HELPS > learn more

At Merck, we believe no one should go without the medicines or vaccines they need. For more information about our patient assistance programs, visit merckhelps.com

PRODUCT PIPELINE

> view

Visit our new interactive pipeline, featuring a wide range of product candidates across each phase of development.



MERCK AND PARTNERS LAUNCH PINK RIBBON-RED RIBBON CANCER INITIATIVE > learn more

f

Merck is helping to address the cervical and breast cancer crises in developing nations.



8

You

THE MERCK MANUALS

Merck is committed to providing high-quality medical information to patients and healthcare providers. That's why we proudly offer The Merck Manuals free online.



Lonza

rch Go



print 🕒

Products & Services

Products & Applications
Research Products
Custom Media & Bioprocess Containers
Nutrition
Personal Care & Cosmetics
Rapid Testing Solutions
Endotoxin Detection
Other Products & Services
REACH
Custom Manufacturing
Overview
Advanced Chemical Synthesis
Highly Potent API (HPAPI)
Antibody Drug Conjugates
Peptides Synthesis
Microbial Fermentation
Microbial Biopharmaceuticals
Mammalian Cell Culture
Applied Protein Services
Cell Therapy
Viral-based Therapeutics
1903

Contacts

Shop

Company

About us
Media Center
Investor Relations
Events
Careers
Worldwide
Arch Chemicals Acquisition Offer

Welcome to the world of Lonza

Our markets















BioResearch

Lonza comprises the areas of Cell and Molecular Biology, Drug Discovery and applied research as well as quality control laboratory testing systems including tools for quality control tests for microbial detection.

Pharma&Biotech

We support emerging and established innovators of novel therapeutics from discovery through commerical supply with our manufacturing expertise, advanced technologies and high-quality products.

Nutrition

For human and animal nutrition we offer branded nutritional ingredients backed by scientific evidence and with clear benefits suitable for a wide range of product applications.

MicrobialControl

We offer antimicrobial products in the areas of hygiene, wood and water treatment applications.

Agriculture

We offer custom manufacturing of active ingredients and agrochemical intermediates for agrochemical companies, as well as the world's leading molluscicide Meta[™] metaldehyde.

MaterialsScience

Our products and services are valued by key hightech industries such as aerospace, electronics, telecommunication, automotive, coatings, plastic and wood composites, textiles, powder metal and oilfield.

PersonalCare

We offer unique products and services to meet personal care development needs – from formulation to preservation and testing.

News Center

09/26/2011

Mesoblast and Lonza establish strategic global manufacturing alliance

→ more

09/16/2011


Lonza Group Ltd plans secondary listing on the Main Board of the Singapore Stock Exchange

→ more

09/15/2011

Lonza enters manufacturing agreement with Pasteuria Bioscience for production of a novel bionematicide

→ more



BOTOX®

(ONABOTULINUMTOXINA) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF URINARY INCONTINENCE IN ADULTS WITH NEUROLOGICAL CONDITIONS INCLUDING MULTIPLE SCLEROSIS AND SPINAL CORD INJURY

Clinical Trials Showed Approximately 20 Fewer Urinary Leaking Episodes Per Week At Week Six; BOTOX[®] Proven Effective Up To 10 Months In Patients Who Have An Inadequate Response To Or Are Intolerant Of An Anticholinergic Medication

Read more →

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX[®] (onabotulinumtoxinA), RESTASIS[®] (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN[®] (bimatoprost ophthalmic solution) 0.03%, BOTOX[®] Cosmetic (onabotulinumtoxinA), the JUVÉDERM[®] family of dermal fillers, and the LAP-BAND[®] Adjustable Gastric Banding System. Please look through this Web site for more information, including Important Safety Information, about these products and our full portfolio of products.

AGN NYSE 84.55 (1.44) Volume 1,953,500

SUBMIT

GLOBAL LOCATIONS

Learn about our worldwide locations.

NEWS & EVENTS

- 09.21.11 National Headache Foundation, HealthyWomen and Allergan Offer People Living With Chronic Migraine a Chance to "Rewrite Your Day"
- 08.24.11 BOTOX® (onabotulinumtoxinA) Receives U.S. FDA Approval for the Treatment of Urinary Incontinence in Adults with Neurological Conditions Including Multiple Sclerosis and Spinal Cord Injury
- 08.08.11 Allergan's BOTOX® Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury

More news→

Information posted to this Web site is intended for U.S. residents. Please visit the local Allergan Web site for your country for information concerning Allergan products and services available in your country of residence.

^{@ 2011} Allergan, Inc. All Rights Reserved. Site Map | Privacy & Terms



Recent Blog Posts



"Adipose-opathy": A New Way to View the Metabolic Danger of Obesity

Spotlight





OUR SERVICES OUR RESULTS **ABOUT VILLAGEHEALTH NEWS & EVENTS**

Working together to enhance the care of patients with kidney disease

YOUR VILLAGEHEALTH

Patient or Member

Payors

Physicians & Healthcare Professionals

Company Overview

VillageHealth is comprised of a dedicated team of specially trained nurses and professionals providing integrated care management to patients with kidney disease throughout the US. We provide services to help improve the lives of our patients by working with them to prevent complications, reduce the number of avoidable hospitalizations and improve overall health.

VillageHealth is not a one-size-fits-all approach, but our integrated care management services are formulated to meet the unique needs of each patient. We work with you, your PCP and the entire care team to develop a personalized plan of care. Working together we can enhance the care of patients with kidney disease.

VillageHealth ICM Approach

Using an Integrated Care Management (ICM) approach, VillageHealth strives to make sure that valuable resources are used effectively, creating an enhanced patient experience and improved clinical outcomes. The VillageHealth ICM approach

- · Coordinates care with the patient, physician(s) and provider
- · Educates and engages patients to take an active role in their health care
- · Provides a patient centric approach to care backed by proven results

Interested in learning more about VillageHealth?

- Patient or Member
- Payors / Providers
- Physicians and Healthcare Professionals
- Careers VillageHealth Nurse DaVita Connection > Success Stories from the field

Success Stories

Health helps me feel better. My ... more 37



GO

VillageHealth Tip-of-the-Month



The Higher Your Cholesterol, The Greater The Risk Of Developing Heart Disease.

High blood cholesterol affects over 65 million Americans. September is National Cholesterol Education Month. Learn about the different types of cholesterol, what your numbers mean and more.

Click here to learn more.

© 2010 VillageHealth Disease Management. All rights reserved. This site is for informational purposes only and is not intended to be a substitute for medical advice from a physician. Please check with a physician if you need a diagnosis and/or for treatments as well as information regarding your specific condition. If you are experiencing urgent medical conditions, call 9-1-1.




11 The Key to Better



Narrowing It Down





Avenir Medical is setting a new trend in surgical technology. Our flagship surgical navigation tool for hip replacement, PelvAssist[™], developed in collaboration with top orthopaedic surgeons, promises to transform today's traditional implant alignment methods to improve patient outcomes. Avenir's breakthrough technology offers surgeons and hospitals a cost effective and reliable improvement to hip replacement procedures.



For Surgeons

PelvAssist™ provides surgeons with precise implant positioning information, without the complication of traditional navigation



For Patients

Approximately 1 in 40 hip replacements are not properly aligned the first time and need correction. Our product gives patients peace of mind.



For Hospitals

Unnecessary revisions not only hurt the patient - they hurt a hospital's budget. PelvAssist™ saves dollars by reducing the risk of repeat surgeries.

Our Product: PelvAssist™

For orthopaedic surgeons and hospitals seeking to improve patient outcomes of hip replacement surgery. <u>Learn More.</u>

Contact Us Today


Reach us at: info@avenirmedical.com (519) 342-3178


What's New

July 19th, 2011 Avenir Medical places in top 5 of over 600 applicants in VISA elevator pitch competition... in an actual elevator. <u>Full story</u>.

April 27th, 2011 Avenir Medical, recipient of the Spinmaster Innovation Fund, is featured in a live interview on the Business News Network. View the clip now.

May 18th, 2010 Avenir Medical wins first prize at the OCE Discovery 2010 conference in the Ontario's Next Top Entrepreneur competition.





All content @ Midmark Corp. 2011 | Privacy Policy | Site Map | Webmaster | Contact Us | 1-877-503-3756 | 📘 📊 🧲 ShareThis

Because we care.™

Global Web Site Roche Worldwide Deutsch Site Map Contact + Text Size -

Roche

Search for...

Q

Home About Roche Products Corporate Responsibility Research & Development Media Investors Careers

We Innovate Healthcare. Because every life counts.

Click on the photographs to see some of the ways we make a difference to patients with cancer every single day.





© 2011 F. Hoffmann-La Roche Ltd Legal Statement Privacy Policy 27,09.2011


This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.

Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.



Search

Contact Us Email Alerts





About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. Learn More

News Releases

Santarus Announces Supportive Top-Line Results from Budesonide MMX Extended Use Study

Santarus to Present at September Investment Conferences

Santarus and Depomed Announce New U.S. Commercialization Agreement for GLUMETZA Prescription Products

More News

Products



CYCLOSET[®] (bromocriptine mesylate) CYCLOSET is a first-in-class antidiabetic treatment that may lower your blood sugar, without increasing insulin.



GLUMETZA® (metformin hydrochloride extended release tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As with all metformin products, GLUMETZA has a boxed warning for lactic acidosis. Please click here for Important Safety Information and Full Prescribing Information, including boxed warning.



ZEGERID[®] (omeprazole/sodium bicarbonate) is an immediate-release oral proton pump inhibitor (PPI) used in adults for up to 4 weeks to treat heartburn and other symptoms that happen with gastroesophageal reflex disease (GERD).

Pipeline

Learn More Have Questions? Request Medical Information





Increase the probability of rare, highquality and high-yielding clones with ClonaCellTM.

> Request Sample



ClonaCell™ FLEX - create customized medium for any cell type.

> Request Sample



Request your copy of "Identity and Properties of Mesenchymal Stem Cells", our new wallchart collaboration with Nature Reviews Molecular Cell Biology.

> Read More

Enter a catalog number to add an item to your shopping cart.



E-Newsletter Sign Up

Subscribe to receive email updates from STEMCELL Technologies.

Sign Up Now!

Connect with STEMCELL



STEMCELL Technologies Ind's quality management system is certified to ISO 13485,20003

© 2011, STEMCELL Technologies. All rights reserved

Shop Create An Account Order Online Ordering Information New Products Catalog

Careers About STEMCELL Privacy Policy Stem Cell Information

Company

Contact Us

Connect with STEMCELL


E-newsletter Sign-up



Sitemap

javascript:void(0);





What is Pump Therapy? More

At Tandem Diabetes Care, Inc. we're deep in the process of product development and are using patented, cutting-edge technology to provide what you've been asking for in insulin administration. Through the process of working with over 1,000 educators and pump users, we have developed a deep understanding of the unmet needs for pump therapy and we intend to address them.

Technology advancements aren't just for gadgets and entertainment – at least not anymore ... we're advancing your options and provide the solutions you want for diabetes management. Change your pump and stop changing your life. News & Events More

LATEST NEWS

13 OCT 2008 Tandem Diabetes Care Announces Clinical Advisory Board

UPCOMING EVENT

14 AUG 2008 Tandem Diabetes Care Announces Plans for New Corporate Headquarters San Diego, CA




Senior Mechanical Engineer, Disposables Development

SEARCH

Senior Mechanical Engineer, Product Design

Senior Manager, User Experience Design

Legal Policy Privacy Policy Site Map Copyright © 2009 Tandem Diabetes Care. All rights reserved





Sangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Learn More About Sangart →

Products More

During more than 30 years of extensive research, Sangart has refined the pegylation of human hemoglobin to create a proprietary molecule, MP4, with the ability to perfuse oxygen deprived tissues and carry oxygen through the circulatory system to prevent and treat ischemia (oxygen deprivation of tissues).

MP4OX

MP4OX is designed to deliver oxygen in the capillaries, where red blood cells may not naturally reach when the body is suffering from traumarelated ischemia. Please click here for a short animation describing MP4OX's unique mechanism of action.

MP4CO

MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) and then provide oxygen delivery for patients with sickle cell anemia suffering from a sickle cell crisis.

Product Pipeline

Sangart is developing a number of additional, earlier stage pipeline products based on its core technology and unique understanding of oxygen delivery.

Research More

Built on a strong foundation of scientific research, Sangart is dedicated to continuing its comprehensive clinical trial program to study and develop its products for patients in need.

Trauma

Studying MP4OX's ability to benefit patients suffering from trauma.

Sickle Cell Anemia

Studying MP4CO's ability to benefit sickle cell anemia patients.

Please click here for a broadcast segment on sickle cell disease featuring Sangart.

Other Conditions Clinical Trials

Latest News

14 June 2011 Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients with Hemorrhagic Shock

19 April 2011 Sangart Announces Closing of \$50 Million Series G Financing

06 Dec 2010 Sangart, Inc. Announces Cooperative Research and Development Agreement wth U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury

Моге

The "Mocked Up" Site





PRODUCTS EVIDENCE INVESTORS BLOG ABOUT CONTACT



First Nursing Scholar Raises Awareness About Patients in Need in Kalamazoo

A local nursing student and first-time recipient of a unique Pfizer scholarship is raising awareness about patients who are struggling to receive health care by writing about her experience this summe at a community health care center in Kalamazoo. Mich WHY BIOLIFE?



Products More

During more than 30 years of extensive research, Sangart has refined the pegylation of human hemoglobin to create a proprietary molecule, MP4, with the ability to perfuse oxygen deprived tissues and carry oxygen through the circulatory system to prevent and treat ischemia (oxygen deprivation of tissues).

MP4OX



igned to deliver oxygen in the ere red blood cells may not naturally e body is suffering from traumania. Please click here for a short icribing MP4OX's unique mechanism

MP4CO



igned to deliver therapeutic levels of ide (CO) and then provide oxygen ients with sickle cell anemia suffering :ell crisis.

Product Pipeline



eloping a number of additional, ipeline products based on its core d unique understanding of oxygen

Evidence More

Built on a strong foundation of scientific research, Sangart is dedicated to continuing its comprehensive clinical trial program to study and develop its products for patients in need.

Trauma

Studying MP4OX's ability to benefit patients suffering from trauma.

Sickle Cell Anemia

Studying MP4CO's ability to benefit sickle cell anemia patients.

Please click here for a broadcast segment on sickle cell disease featuring Sangart.

Other Conditions Clinical Trials

Latest News

14 June 2011 Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients with Hemorrhagic Shock

19 April 2011 Sangart Announces Closing of \$50 Million Series G Financing

06 Dec 2010 Sangart, Inc. Announces Cooperative Research and Development Agreement wth U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury

More

Events

19 April 2011 Sangart Announces Closing of \$50 Million Series G Financing

Connect with BioLife





We develop next generation, patented hypothermic storage and cryopreservation media products that extend shelf life and improve post preservation viability and performance of cells, tissues, and organs.

Our Products

GMP. SERUM-FREE, PROTEIN-FREE BIOPRESERVATION MEDIA PRODUCTS

HypoThermosol[®]

Storage and Shipping Media Proprietary, best-in-class serum-free, protein-free, GMP-grade storage/shipping media for cells, tissues, and organs

Cryo Stor[®]

DI 101 8

Freeze Media Pre-Formulated with DMSO

Proprietary, serum-free, protein-free, GMP-grade freeze media for cells, tissues, and organs

News

read more

THE LATEST FROM BIOLIFE SOLUTIONS

July 25, 2011 CAREERS: TWO POSITIONS read more

July 6, 2011 RECORD QUARTERLY REVENUE BioLife successfully finishes fourth

BIOLIFE LEADER IN UMBILICAL

CORD BLOOD STEM CELL

consecutive month of report revenues! ISEH 40th Annual Scientific Meeting June 21, 2011

Vancouver, Canada August 25-28, 2011

FDA

Events

MASTER FILE REQUEST FORM

ISO 13485 2003 CERTIFIED

Stem Cells Europe

Edinburgh, Scotland

July 20-21, 2011

MSC 2011

Cleveland, OH

August 22-24, 2011



BIOLIFE SOLUTIONS

First Nursing Scholar Raises Awareness About Patients in Need in Kalamazoo

FD/A

PRODUCTS EVIDENCE INVESTORS BLOG ABOUT CONTACT

WHY BIOLIFE?

SEARCI

Sangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Learn More About Sangart →

Products More

During more than 30 years of extensive research, Sangart has refined the pegylation of human hemoglobin to create a proprietary molecule, MP4, with the ability to perfuse oxygen deprived tissues and carry oxygen through the circulatory system to prevent and treat ischemia (oxvoen deprivation of tissues)

MP4OX

igned to deliver oxygen in the ere red blood cells may not naturally e body is suffering from traumaha. Please click here for a short cribing MP4OX's unique mechanism

MP4CO

1

igned to deliver therapeutic levels of ide (CO) and then provide oxygen 1 ients with sickle cell anemia suffering ell crisis

Product Pipeline

Evidence More

Built on a strong foundation of scientific research, Sangart is dedicated to continuing its comprehensive clinical trial program to study and develop its products for patients in need.

Trauma

Studving MP4OX's ability to benefit patients suffering from trauma.

Sickle Cell Anemia Studying MP4CO's ability to benefit sickle cell anemia patients.

Please click here for a broadcast segment on sickle cell disease featuring Sangart.

Other Conditions **Clinical Trials**

eloping a number of additional. ipeline products based on its core 1 unique understanding of oxygen





Copyright @ 2009 Tandem Diabetes Care. All rights reserved

Latest News 14 June 2011

Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients with Hemorrhagic Shock

19 April 2011 Sangart Announces Closing of \$50 Million Series G Financing

06 Dec 2010 Sangart, Inc. Announces Cooperative Research and Development Agreement with U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury

Моге

Events

19 April 2011 Sangart Announces Closing of \$50 Million Series G Financing

Connect with BioLife




Legal Policy Privacy Policy Site Man


The New Site





After three days in the cold, do your cells look like those on the left or those stored in HypoThermosol7.





Biopreserved in HypoThe

1,000 Sample Giveaway

*

BioLife Solutions manufactures and markets proprietary protein-free, serum-free cGMP biopreservation media for cells, tissues, and organs. We perform contract R & D and offer biopreservation protocol consulting. And for select customers, we perform custom formulation, fill, and finish services. More about Biolife ---

III. III.

Products



CryoStor[®] Pre-formulated with 2, 5, 10%, or a custom volume of USP-grade

DMSD, CryoStor yields superior post-thaw cell viability, recovery, and function. Serumtree and protein-free!



#2-8°C.

Protein-free, serum-free hypothermic storage media are designed for maximum shelf life and shipping stability



BloodStor cGMP cryopreservation media for freezing stem cells isolated from

umbilical cord blood, peripheral blood, and bone marrow. Formulated with 55% USP-grade DMSO, 5% USP-grade Dextran, and WFI-quality water.

Services

Contract Research Leverage our expertise to optimize your biopreservation protocols.

Formulation, Fill, and Finish Outsource your biopreservation media manufacturing to BioLife.

Evidence

Cryofitor versus Atternative Cryopresensition Nedla

HypoThermosol versus Alternative Hypothermic Storage

BioPreservation Today® Archives



Latest News

BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue Press Releases >>

CEO Interview - The Wall Street Transcript Read Transcript. **

BioLife is giving away 1,000 samples of biopreservation media to researchers and clinicians in the regenerative medicine, cell biobanking, and drug discovery industries. Hew to Participale. **

Why Trypan Blue is a misleading standard Find out why, ++

How switching your biopreservation media improves your economics. 'Made my project viable' >>

Events

International Society for Cellular Therapy Annual Meeting, June 5-8, 2012

See all events >>

Connect with BioLife



Evidence





Terma & Conditions | Privacy





1,000 SAMPLE GIVEAWAY

We're giving away 1,000 free samples of our cGMP biopreservation media. See the results for yourself!

email address

GET A VIAL





CryoStor cryopreservation freeze media





BioLife Solutions manufactures and markets proprietary protein-free, serum-free cGMP biopreservation media for cells, tissues, and organs. We perform contract R & D and offer biopreservation protocol consulting. And for select customers, we perform custom formulation, fill, and finish services. More about Biolife \rightarrow

Products



CryoStor[®]

Services

Contract Research Leverage our expertise to optimize your

Latest News

BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue

Contact

JHage@MedicalMarcom.com

LinkedIn http://linkd.in/MDGroup

PDF of 33 Featured Websites MedicalMarcom.com/Design



